Ligand Pharmaceuticals Incorporated (LGND)

Ligand reported strong Q1 2025 results, surpassing EPS and revenue forecasts, with revenue rising by 46% year-over-year. Ligand reported Q2 2025 total revenues increased by 15% and raised its full-year 2025 revenue and adjusted EPS guidance. Director John W. Kozarich sold 934 shares of common stock. Ligand completed an offering of $460 million in convertible senior notes. Ligand's partner SQ Innovation received FDA approval for Lasix® ONYU. Ligand Pharmaceuticals' stock reached a new 52-week high, and several brokerages increased their target prices. Ligand announced it would report its third-quarter 2025 financial results on November 6, 2025. Ligand announced it would host an Investor Day in New York City on December 9, 2025.

Information regarding specific demand seasonality patterns for Ligand Pharmaceuticals' products and services is not publicly available. The company's diversified revenue streams across partnered drugs and technology licenses may mitigate significant seasonality impacts. Ligand's business model focuses on generating royalties and sales of its Captisol technology, aiming to create a sustainable and consistent revenue stream.

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring and developing royalty-generating assets and licensing its technologies. The company concentrates on drug discovery and early-stage development, partnering with other companies for later stages. Ligand generates revenue through royalties, milestones, and licensing payments. Its portfolio includes royalty rights to approximately 90 pharmaceutical products across various therapeutic areas. Major products and technologies include Captisol, which improves drug solubility, and the OmniAb Platform, used for discovering human antibodies. Royalty-bearing commercial products include Kyprolis, Evomela, Filspari, Vaxneuvance, Ohtuvayre, Capvaxive, Qarziba, Zelsuvmi, Nexterone, Rylaze, Teriparatide Injection, Pradefovir, Posaconazole, Voriconazole, MenFive, NOXAFIL, Duavee, and Viviant/Conbriza.

Ligand Pharmaceuticals' commercial programs are marketed in more than 70 countries worldwide.

Ligand Pharmaceuticals has maintained a positive brand perception, driven by its strategic business model and financial performance. Analysts have shown strong market confidence in the company's strategy, with buy ratings reported. This positive sentiment is attributed to Ligand's focus on expanding its royalty portfolio, converting innovation into cash flow, and its continued investment in research and development. The company's pipeline and ability to address global health challenges also contribute to its reputation.

Ligand Pharmaceuticals Incorporated has a mixed ownership structure. Institutional investors hold approximately 73.08% of the stock, with major holders including BlackRock, Inc. and Vanguard Group Inc. Insiders own approximately 2.43% of the stock. Public companies and individual (retail) investors hold the remaining shares, approximately 24.48%.